• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

    2/14/24 4:40:04 PM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEGN alert in real time by email
    SC 13G/A 1 p24-0549sc13ga.htm LEGEND BIOTECH CORP

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Legend Biotech Corporation

    (Name of Issuer)
     

    Ordinary Shares, par value of $0.0001 per share

    (Title of Class of Securities)
     

    52490G102**

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 52490G102 has been assigned to the American Depositary Shares ("ADSs") of the Company, which are quoted on The NASDAQ Global Select Market under the symbol "LEGN." Each ADS represents 2 Ordinary Shares.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 52490G10213G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Investment Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    13,052,732*

    6

    SHARED VOTING POWER

    -0-

    7

    SOLE DISPOSITIVE POWER

    13,052,732*

    8

    SHARED DISPOSITIVE POWER

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,052,732*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%*

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of 1,083,632 Ordinary Shares attributable to the holdings of a fund managed by HHLR (as defined in Item 2(a) below) and 11,969,100 Ordinary Shares attributable to the holdings of a fund managed by HIM (as defined in Item 2(a) below). HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

    CUSIP No. 52490G10213G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    HHLR Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    13,052,732*

    6

    SHARED VOTING POWER

    -0-

    7

    SOLE DISPOSITIVE POWER

    13,052,732*

    8

    SHARED DISPOSITIVE POWER

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,052,732*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%*

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of 1,083,632 Ordinary Shares attributable to the holdings of a fund managed by HHLR and 11,969,100 Ordinary Shares attributable to the holdings of a fund managed by HIM. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

     

     

    CUSIP No. 52490G10213G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Legend Biotech Corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.
    Item 2(a). NAME OF PERSON FILING
     

    This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM"), with respect to Ordinary Shares attributable to the holdings of LGN Holdings Limited ("LGN") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"), with respect to Ordinary Shares attributable to the holdings of HHLR Fund, L.P. ("HHLR Fund"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." LGN is wholly owned by Hillhouse Investment Management V, Ltd., whose sole shareholder is Hillhouse Fund V, L.P. ("Fund V"). Fund V is managed and controlled by HIM. HIM is hereby deemed to be the sole beneficial owner of, and to solely control the voting and investment power of, the Ordinary Shares attributable to the holdings of LGN. HHLR acts as the sole investment manager of HHLR Fund. HHLR is hereby deemed to be the beneficial owner of, and to control the voting and investment power of, the Ordinary Shares attributable to the holdings of HHLR Fund. HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, each of HHLR and HIM reports on this Schedule 13G/A that it has shared voting and dispositive power of the Ordinary Shares beneficially owned by each of HHLR and HIM.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of the Reporting Person is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006.

     

    Item 2(c). CITIZENSHIP
      Cayman Islands

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Ordinary Shares, par value of $0.0001 per share (the "Ordinary Shares").
    Item 2(e). CUSIP NUMBER
      There is no CUSIP number assigned to the Ordinary Shares.  CUSIP number 52490G102 has been assigned to the ADSs.
    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;

     

     

     

    CUSIP No. 52490G10213G/APage 5 of 7 Pages

     

      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ________________________________

     

    Item 4. OWNERSHIP
      The percentage set forth in this Schedule 13G/A is calculated based upon an aggregate of approximately 363,577,853 Ordinary Shares reported to be issued and outstanding as of September 30, 2023, as reported in the Company’s Form 6-K filed with the Securities and Exchange Commission on November 20, 2023.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

     

     

    CUSIP No. 52490G10213G/APage 6 of 7 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each Reporting Person hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 52490G10213G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 14, 2024

     

    HILLHOUSE INVESTMENT MANAGEMENT, LTD.  
       
       
    /s/ Audrey Woon  
    Name: Audrey Woon  
    Title: Chief Compliance Officer  

     

     

    HHLR Advisors, LTD.  
       
       
    /s/ Audrey Woon  
    Name: Audrey Woon  
    Title: Chief Compliance Officer  

     

     

     

     

    Get the next $LEGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LEGN

    DatePrice TargetRatingAnalyst
    10/8/2024$86.00Buy
    Redburn Atlantic
    6/17/2024$88.00Buy
    Truist
    5/24/2024$86.00 → $73.00Buy
    H.C. Wainwright
    5/23/2024$60.00Buy
    Deutsche Bank
    4/17/2024$65.00Sector Perform → Sector Outperform
    Scotiabank
    4/3/2024$82.00Overweight
    Cantor Fitzgerald
    3/13/2024$86.00Outperform
    Raymond James
    12/19/2023Sector Perform
    Scotiabank
    More analyst ratings

    $LEGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

      SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours

      4/29/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

      CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide financial runway into the second quarter of fiscal year 2026 SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell thera

      3/11/25 7:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

      SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's quarter and fiscal year performance. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation s

      2/25/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    SEC Filings

    See more
    • SEC Form 6-K filed by Legend Biotech Corporation

      6-K - Legend Biotech Corp (0001801198) (Filer)

      4/15/25 7:30:15 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Legend Biotech Corporation

      144 - Legend Biotech Corp (0001801198) (Subject)

      3/25/25 12:15:16 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Legend Biotech Corporation

      20-F - Legend Biotech Corp (0001801198) (Filer)

      3/11/25 4:02:47 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

      SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

      11/14/24 1:22:39 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

      SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

      11/12/24 10:32:10 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Legend Biotech Corporation (Amendment)

      SC 13G/A - Legend Biotech Corp (0001801198) (Subject)

      4/5/24 12:18:27 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Legend Biotech with a new price target

      Redburn Atlantic initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $86.00

      10/8/24 7:29:11 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Legend Biotech with a new price target

      Truist initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $88.00

      6/17/24 7:33:12 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Legend Biotech with a new price target

      H.C. Wainwright reiterated coverage of Legend Biotech with a rating of Buy and set a new price target of $73.00 from $86.00 previously

      5/24/24 7:45:26 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    Financials

    Live finance-specific insights

    See more
    • Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

      SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours

      4/29/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

      CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide financial runway into the second quarter of fiscal year 2026 SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell thera

      3/11/25 7:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

      SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's quarter and fiscal year performance. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation s

      2/25/25 8:00:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Legend Biotech Appoints Alan Bash as President of CARVYKTI®

      SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg

      11/4/24 7:30:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

      SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn

      10/3/24 7:30:00 AM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

      SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9. "We are pleased to welcome Dr. Salovey to the Legend Board," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Dr. Salovey's deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic dec

      8/8/24 4:05:00 PM ET
      $LEGN
      Biotechnology: Pharmaceutical Preparations
      Health Care